MAOA and Alzheimer disease: Their inhibitory activities against AChE, BChE, MAO-A, MAO-B, and BACE-1 were evaluated, and kinetic and reversibility studies, cytotoxicity tests, in silico pharmacokinetics, and docking simulations were performed to identify novel candidate compounds for the treatment of AD and PD.